Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
CRDL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.09 - C$4.26
Previous CloseN/A
Volume34.34K
Average Volume (3M)97.65K
Market Cap
$108.22M
Enterprise ValueC$120.88M
Total Cash (Recent Filing)C$2.36M
Total Debt (Recent Filing)C$190.04K
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 18, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding82,608,990
10 Day Avg. Volume114,671
30 Day Avg. Volume97,647
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.14Price Target Upside750.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cardiol Therapeutics News
PremiumCompany Announcements
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses
PremiumCompany Announcements
Cardiol Therapeutics Schedules Annual General Meeting for May 2025
PremiumCompany Announcements
Cardiol Therapeutics to Present at TD Cowen Health Care Conference---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCardiolRx has advanced into Phase 3 study.
Efficacy DataMAvERIC-Pilot results were compelling, showing marked improvements in both pericarditis pain and inflammation.
Bears Say
Competitive DifferentiationRisks to the investment thesis include failure of products to show sufficient competitive differentiation in targeted product indications.
Risk FactorsRisks include failure of clinical trials to prove efficacy, regulatory requirements for additional studies, and potential inability to raise additional funds under poor market conditions.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.34% Insiders
0.06%
Mutual Funds
7.11% Other Institutional Investors
85.99% Public Companies and
Individual Investors
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.09 and its highest was C$4.26 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $108.22M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 125 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is 0.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 82,608,990 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
---
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$11.14 (750.72% Upside)
C$11.14 (750.72% Upside)
Blogger Sentiment
Bullish
TSE:CRDL Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $21.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.17%
12-Months-Change
Fundamentals
Return on Equity
-138.82%
Trailing 12-Months
Asset Growth
-20.40%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
---
CRDL Stock 12 Month Forecast
Average Price Target
C$11.14
▲(750.72% Upside)
Technical Analysis
Theratechnologies
―
Resverlogix
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Best Analysts Covering CRDL
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
+4.58%
reiterated a buy rating 15 days ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +4.58% per trade.
---